By Maggie Fick and Kashish Tandon LONDON/BENGALURU (Reuters) -Drugmaker stocks gained a temporary reprieve on Thursday as U.S ...

Shares of DexCom Inc. DXCM shed 9.30% to $61.80 Thursday, on what proved to be an all-around grim trading session for the ...

Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A ...

Eligible residents living with diabetes in Saskatchewan who rely on any type of insulin may be eligible to receive coverage ...

DexCom Inc. closed 52.01% short of its 52-week high of $141.99, which the company achieved on April 9th.

Bundee Aki and Mack Hansen have been helpful to Gavin as he finds his feet at this level and after a couple of campaigns with ...

DexCom's recent licensing deal with Nanowear is likely to reinforce the broader potential of CGMs in continuous metabolic ...

Sales of Beta Bionics insulin pumps spiked 145% in the fourth quarter behind solid new patient starts. Elsewhere, former ...

Building iteration into the product commercialization process can help life sciences companies avoid many of the missteps ...

Anderson notes that biopharma has been sheltered from tariffs for decades, including during the first Trump administration, however this time around the administration placed tariffs on pharmaceutical ...

Josh Adams and Taulupe Faletau are set to provide an injury boost for Cardiff before the Challenge Cup last-16 tie against ...

Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, applauds this decision as a testament to the government’s commitment to ...